New Hope on the Horizon: PulseSight Therapeutics Enters the Retinal Disease Landscape
The inherited retinal disease (IRD) community is closely watching new developments in gene therapy, and the recent launch of PulseSight Therapeutics brings a promising new approach to the forefront. This new ophthalmic biotech company is dedicated to developing non-viral gene therapies for severe retinal diseases, offering a potential alternative to existing treatments and expanding the therapeutic landscape for conditions that can lead to blindness. For patients and families navigating the challenges of IRDs, advancements in gene therapy represent a significant step toward preserving and potentially restoring vision.
PulseSight Therapeutics, based in Paris, France, officially launched on February 28, 2024, with seed financing from venture capital funds Pureos Bioventures and ND Capital, and Korea Investment Partners also joined the seed financing round. The company aims to clinically validate its proprietary non-viral gene therapy ocular platform. This platform utilizes an electro-transfection system to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to treat major eye diseases. The technology has reportedly been validated in a Phase I/II clinical study, demonstrating a good safety profile of both the plasmid and the delivery system, along with a long-lasting clinical benefit of up to eight months in patients with chronic noninfectious uveitis.
The company's pipeline includes two late-stage preclinical drug candidates initially targeting age-related macular degeneration (AMD), specifically wet AMD and dry AMD, including geographic atrophy (GA). The lead program, PST-809, is designed for wet AMD and involves a dual-gene plasmid encoding for aflibercept (an anti-VEGF) and decorin, an anti-angiogenic and anti-fibrotic protein. Preclinical studies for PST-809 have reportedly shown superior efficacy compared to intravitreal aflibercept in reducing vascular leakage and promoting retinal pigment epithelium (RPE) wound healing. This could potentially reduce the need for frequent injections, aiming for one injection every six months. The second program, PST-611, targets geographic atrophy and uses a plasmid encoding the human transferrin protein, which is involved in controlling iron levels in the eye. PST-611 has also been awarded orphan drug designation by the FDA and EMA for other neurodegenerative retinal disorders, such as glaucoma or retinitis pigmentosa.
For patients and families affected by IRDs, the emergence of companies like PulseSight Therapeutics underscores a growing focus on innovative treatment modalities. Non-viral gene therapy approaches, such as the one being developed by PulseSight, could offer advantages like potentially safer delivery and the ability to carry larger genetic payloads compared to some viral vectors. The prospect of therapies requiring less frequent administration, as suggested for PST-809 and PST-611, could also significantly improve the quality of life for individuals undergoing treatment for chronic retinal conditions.
While these programs are currently in preclinical stages for AMD, the broader implications for gene therapy development, especially for conditions like retinitis pigmentosa, are encouraging. The company is currently raising a Series A financing round to advance its programs into clinical proof-of-concept. The IRD community will eagerly anticipate further updates as PulseSight Therapeutics progresses its research and development efforts, potentially paving the way for new therapeutic options in the future.